Understanding RAPID and TAP: Strategic Biocompatibility Planning for Breakthrough Medical Devices

On April 23, 2026, the Centers for Medicare & Medicaid Services (CMS) and the FDA announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, a groundbreaking initiative designed to accelerate Medicare beneficiary access to FDA-designated Breakthrough Devices. Combined with the expanding Total Product Life Cycle Advisory Program (TAP), these programs fundamentally change how manufacturers should approach development strategy, evidence generation, and biocompatibility evaluation for innovative medical devices.

For medical device manufacturers, regulatory affairs professionals, and CROs supporting Breakthrough device development, understanding how RAPID and TAP work together—and what they mean for biocompatibility strategy—is essential for successful commercialization in 2026 and beyond.

What is the RAPID Coverage Pathway?

The RAPID coverage pathway addresses a longstanding challenge in medical device innovation: the gap between FDA market authorization and Medicare coverage. Historically, even after FDA approval or clearance, manufacturers faced approximately a year or more waiting for Medicare national coverage determinations, delaying patient access and market adoption.

RAPID changes this timeline dramatically. For eligible Breakthrough Devices, CMS will issue a proposed National Coverage Determination (NCD) the same day the device receives FDA market authorization. After the statutorily required 30-day public comment period, predictable Medicare national coverage and payment can occur as soon as two months after market authorization—compared to a year or more under traditional pathways.

Eligibility Requirements for RAPID

Not all devices qualify for RAPID. The pathway is available for:

• Breakthrough-designated devices addressing unmet medical needs among Medicare beneficiaries

• Class II devices participating in FDA's Total Product Life Cycle Advisory Program (TAP)

• Class III devices regardless of TAP participation

• Devices with IDE studies that enroll Medicare beneficiaries and study clinical health outcomes agreed upon by both FDA and CMS

This coordinated approach allows CMS and FDA to rely on the same premarket evidence for both FDA review and Medicare coverage processes, reducing duplication and improving efficiency.

How RAPID Works in Practice

The key innovation of RAPID is early alignment between FDA and CMS on what evidence matters. Through the pathway, CMS becomes part of early and frequent engagement between FDA and device innovators. This means manufacturers can understand what clinical outcomes are most relevant for Medicare beneficiaries during device development, not after FDA authorization.

By aligning evidence expectations earlier, RAPID provides:

• Reduced duplication of evidence generation efforts

• Improved efficiency in both regulatory and coverage processes

• Increased transparency for innovators about requirements

• Predictable timelines from development through Medicare coverage

• Cost savings by eliminating post-approval evidence generation for coverage

Understanding the TAP Program

The Total Product Life Cycle Advisory Program (TAP) is FDA's voluntary program providing enhanced engagement for devices of public health importance. Launched as part of the Medical Device User Fee Amendments (MDUFA) V reauthorization, TAP's primary goal is expediting patient access to innovative medical devices through early, frequent, and strategic communications with FDA.

What TAP Provides

• Dedicated FDA advisors who proactively provide solutions-focused engagement tailored to each innovator's needs

• Early and frequent communication throughout device development, not just at formal submission milestones

• Strategic guidance on regulatory pathways, evidence generation, and market access

• Facilitated engagement with other key parties relevant to device development and commercialization

As of April 23, 2026, 122 devices are enrolled in the TAP Pilot, with the program continuing to expand across CDRH divisions.

TAP Eligibility and Expansion

TAP is currently accepting enrollment requests for Breakthrough-designated devices and those included in the Safer Technologies Program (STeP) reviewed by multiple CDRH offices, including:

• Division of Ophthalmic Devices

• Office of Cardiovascular Devices

• Office of Neurological and Physical Medicine Devices

• Office of Orthopedic Devices

• Office of Radiological Health

• Division of Renal, Gastrointestinal, Obesity and Transplant Devices (added May 1, 2026)

• Office of Surgical and Infection Control Devices (added May 1, 2026)

On July 1, 2026, TAP will expand further to include divisions covering dental devices, anesthesia and respiratory devices, obstetrical and gynecological devices, injection and infusion devices, and in vitro diagnostics.

How TAP Supports RAPID Pathway Participation

For Class II Breakthrough devices, TAP participation is required for RAPID pathway eligibility. Even for Class III devices where TAP participation is optional, the program provides valuable early engagement to clarify evidence expectations that will satisfy both FDA premarket review and CMS coverage requirements.

TAP advisors can help manufacturers understand what biocompatibility evidence, clinical outcomes data, and safety information will be needed throughout the device lifecycle, allowing strategic planning that supports both regulatory approval and Medicare coverage.

Biocompatibility Strategy Implications for RAPID Pathway Devices

The RAPID pathway's emphasis on early evidence alignment and accelerated timelines has significant implications for how manufacturers should approach biocompatibility evaluation.

Earlier Biocompatibility Evidence Generation

Under traditional pathways, manufacturers sometimes deferred certain biocompatibility activities until late in development or even post-market. RAPID eliminates this option. Because the pathway requires IDE studies enrolling Medicare beneficiaries with clinical outcomes agreed upon by FDA and CMS, biocompatibility evidence must be robust and complete before IDE approval.

Practical implications:

• Material selection and characterization must occur early in design, with clear documentation of biocompatibility rationale

• Chemical characterization under ISO 10993-18 should be conducted during design development, not deferred until premarket submission preparation

• Biological testing strategy must be finalized and justified under ISO 10993-1:2025's risk-based framework before IDE study initiation

• Toxicological risk assessment of extractables and leachables must be completed to support IDE application

Aligning Biocompatibility with Both FDA and CMS Expectations

RAPID requires evidence that satisfies both FDA's premarket safety review and CMS's coverage determination based on clinical benefit for Medicare beneficiaries. This dual requirement affects biocompatibility strategy in several ways:

Patient population considerations become more critical. Medicare beneficiaries may have different risk profiles than general populations due to age, comorbidities, or concomitant medications. Toxicological risk assessment should consider these factors when evaluating margins of safety.

Clinical outcomes focus means biocompatibility evidence must connect to patient-relevant endpoints, not just laboratory test results. How do material choices and biological safety characteristics affect clinical performance and patient outcomes?

Risk-benefit assessment must be comprehensive. CMS evaluates whether clinical benefits justify risks for Medicare beneficiaries. Clear documentation of biological safety supporting favorable risk-benefit conclusions is essential.

Integration with ISO 10993-1:2025 Risk-Based Evaluation

The RAPID pathway's emphasis on early evidence generation and strategic planning aligns well with ISO 10993-1:2025's risk-based biological evaluation framework.

Systematic biological risk assessment required by ISO 10993-1:2025 supports early identification of biocompatibility evidence needs, allowing manufacturers to plan studies that satisfy both FDA and CMS requirements.

Chemical characterization with toxicological risk assessment can efficiently address systemic biological endpoints (systemic toxicity, genotoxicity, carcinogenicity) while minimizing animal testing—important for both regulatory efficiency and animal welfare requirements.

Scientific justification for all testing decisions, required by ISO 10993-1:2025, provides the transparent rationale FDA and CMS need to evaluate evidence adequacy.

Information gathering emphasis in the new standard encourages manufacturers to leverage existing data, literature, and material history before conducting new testing—reducing timelines and costs while maintaining safety assurance.

IDE Study Considerations for Biocompatibility

RAPID pathway devices require IDE studies enrolling Medicare beneficiaries. IDE applications must include comprehensive biocompatibility evaluation demonstrating that device risks are acceptable for the proposed investigation.

Key biocompatibility elements for IDE applications:

• Complete device description including all materials with direct or indirect patient contact, manufacturing processes, sterilization methods, and packaging

• Biological evaluation plan documenting systematic risk assessment, identified biological hazards, and evaluation strategy under ISO 10993-1:2025

• Chemical characterization data for devices where chemical constituents drive biological risk, including extractables/leachables studies and toxicological risk assessment

• Biological test results where testing is necessary to address local tissue effects or other biological endpoints not adequately addressed through chemical characterization

• Risk analysis integrating biocompatibility findings with other device risks and demonstrating acceptable risk-benefit for the proposed clinical investigation

QMSR Quality System Requirements

Manufacturers pursuing Breakthrough designation and RAPID pathway participation must maintain robust quality systems under the QMSR. Biocompatibility evaluation must be integrated with design controls, risk management, and change control processes as required by ISO 13485:2016 and ISO 10993-1:2025.

Design controls integration ensures biocompatibility requirements are translated into design inputs, verified through appropriate testing or analysis, and validated for clinical use.

Change control processes must evaluate biological safety impact when materials, suppliers, manufacturing processes, or sterilization methods change during development or post-market.

Risk management integration under ISO 14971 connects biological hazards identified during biocompatibility evaluation with overall device risk analysis and risk controls.

Strategic Considerations for Manufacturers

Successfully leveraging RAPID and TAP requires strategic planning that integrates regulatory, coverage, and biocompatibility considerations from the earliest development stages.

When to Pursue Breakthrough Designation

Breakthrough Device designation is the gateway to both TAP and RAPID pathways. Manufacturers should consider pursuing designation when:

• The device addresses unmet medical needs for life-threatening or irreversibly debilitating conditions

• The device offers significant advantages over existing alternatives (more effective treatment, earlier diagnosis, improved patient quality of life)

• The device represents innovative technology or mechanism of action

• The target population includes Medicare beneficiaries who would benefit from accelerated coverage

Early pursuit of Breakthrough designation—ideally during device design rather than after development is complete—allows manufacturers to leverage TAP engagement throughout development and plan for RAPID pathway participation.

Leveraging TAP Engagement for Biocompatibility Clarity

For manufacturers enrolled in TAP, the program's early and frequent FDA engagement provides valuable opportunities to clarify biocompatibility expectations before committing to expensive studies.

Use TAP interactions to:

• Discuss biological evaluation strategy and get FDA feedback on risk-based approaches under ISO 10993-1:2025

• Clarify chemical characterization expectations including extraction conditions, analytical methods, and toxicological risk assessment approaches

• Confirm biological testing strategy and scientific justification for testing decisions

• Understand how biocompatibility evidence will be evaluated in context of overall device risk-benefit assessment

• Coordinate evidence generation to satisfy both FDA premarket review and CMS coverage requirements

This proactive engagement reduces risk of late-stage surprises and ensures biocompatibility evidence generated during development will support both regulatory approval and Medicare coverage.

Planning Biocompatibility Work Within Accelerated Timelines

RAPID's accelerated timeline from FDA authorization to Medicare coverage creates pressure to complete all evidence generation, including biocompatibility evaluation, before premarket submission. Manufacturers should:

• Front-load biocompatibility activities by conducting material characterization, chemical characterization, and biological testing early in development

• Plan for parallel activities where possible, such as conducting extractables studies while biological testing is underway

• Engage toxicological expertise early to ensure chemical characterization data will support robust risk assessment without requiring supplemental studies

• Build in contingency time for unexpected findings that may require additional evaluation or material changes

• Maintain clear documentation throughout development to support efficient regulatory submission preparation

Common Pitfalls to Avoid

• Deferring biocompatibility work until late in development, creating timeline pressure and potential delays

• Inadequate material characterization early in design, leading to biocompatibility surprises when formal evaluation occurs

• Poor coordination between biocompatibility strategy and clinical study design for IDE applications

• Insufficient toxicological expertise resulting in chemical characterization data that doesn't support clear safety conclusions

• Weak scientific justification for testing decisions that doesn't satisfy ISO 10993-1:2025 requirements or FDA/CMS expectations

• Failure to consider Medicare population characteristics when conducting toxicological risk assessment

Bottom Line

The RAPID coverage pathway and TAP program represent significant opportunities for manufacturers developing innovative medical devices that address unmet needs for Medicare beneficiaries. By aligning FDA and CMS evidence expectations early and providing predictable timelines from development through Medicare coverage, these programs can dramatically accelerate patient access to breakthrough technologies.

Success in RAPID and TAP requires strategic biocompatibility planning that integrates ISO 10993-1:2025's risk-based evaluation framework with accelerated development timelines and dual FDA/CMS evidence requirements. Manufacturers who front-load biocompatibility activities, leverage TAP engagement for early clarity, and maintain robust quality systems under the QMSR will be best positioned to capitalize on these accelerated pathways.

The key is early, strategic planning that treats biocompatibility not as a late-stage compliance exercise but as an integral part of device development strategy supporting both regulatory approval and market access.

Expert Biocompatibility Strategy for Breakthrough Devices and RAPID Pathway

Successfully navigating RAPID coverage pathway requirements and TAP program engagement requires specialized biocompatibility expertise and strategic planning that integrates regulatory, coverage, and safety considerations from the earliest development stages.

At JL Tox Consulting, we help medical device manufacturers develop comprehensive biocompatibility strategies for Breakthrough devices pursuing accelerated regulatory and coverage pathways.

Our Breakthrough device biocompatibility services include:

• Strategic planning for biocompatibility evidence generation aligned with RAPID pathway timelines

• Biological evaluation planning under ISO 10993-1:2025 risk-based frameworks for Breakthrough devices

• Chemical characterization strategy and toxicological risk assessment for IDE applications

• TAP engagement support helping manufacturers leverage FDA interactions for biocompatibility clarity

• IDE application preparation including comprehensive biocompatibility evaluation documentation

• Risk-benefit assessment considering Medicare beneficiary population characteristics

• QMSR compliance guidance for integrating biocompatibility with design controls and quality systems

With over a decade of specialized experience in medical device biocompatibility and regulatory strategy, Dr. James Lyons and the JL Tox team provide the expertise needed to develop efficient, scientifically defensible biocompatibility strategies that support both FDA approval and Medicare coverage for innovative devices.

Contact JL Tox Consulting to develop your Breakthrough device biocompatibility strategy:

Email: info@JLTox.com

Phone: (877) 899-6568